Acquisition of Late-Stage Selective Phosphate Binder
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 18, 2007--Amgen
(NASDAQ:AMGN) announced today the completion of its acquisition of
Ilypsa, a private company developing non-absorbed drugs for renal
disorders. The transaction provides Amgen with a late-stage phosphate
binder for the treatment of hyperphosphatemia in chronic kidney
disease (CKD) patients on hemodialysis. The acquisition was originally
announced June 4.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science´s promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a deep and broad pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people´s lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
Anne McNickle, 805-447-5890 (media)
Arvind Sood, 805-447-1060 (investors)